Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GPC1 antisense RNA 1 (*GPC1-AS1*) is purported to be a long non-coding RNA transcribed from the antisense strand of the *GPC1* locus. As of September 2025, *GPC1-AS1* is not an established therapeutic target, and its biological roles—if any—are not described in authoritative molecular biology or biomedical literature, in contrast to the well-characterized *GPC1* gene encoding the protein Glypican-1[1][2][3][8]. There is limited or no evidence in main genetic databases (such as GeneCards or UniProt) for a characterized, functional *GPC1-AS1* RNA, and no drugs or disease associations are reported. The *GPC1* gene itself encodes a cell surface heparan sulfate proteoglycan involved in multiple cancer types and cell growth processes[1][2][3][8], but *GPC1-AS1* is distinct and, if it exists at all, has no established function or clinical relevance as of this review. If you are seeking information on the protein "Glypican-1" or the *GPC1* gene product, please clarify; currently, "GPC1 antisense RNA 1" does not map to a recognized or clinically relevant target in the literature or main biological databases[1][2][3][8].
None known
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GPC1 antisense RNA 1 (GPC1-AS1).